Auxly Cannabis Group Inc.
TSX:XLY.TODrug Manufacturers - Specialty & Generic
+$0.00 today
- Market cap
- $364.42M
- Beta
- 1.16
- P/E (TTM)
- 7.3
- EPS (TTM)
- $0.02
Volume 0.13M
Average 0.71M
Returns on capital
Auxly Cannabis Group Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
23.6%
avg -38.7%
ROIC
13.9%
avg -10.3%
ROA
15.4%
avg -17.0%
Analysis
ROE is currently the strongest return metric at 23.6% versus its period average of -38.7%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Hugo Alves | Chief Executive Officer & Director | CAD 2.01M | 54 | — | — |
Michael David Lickver | President | CAD 1.03M | 41 | — | — |
Travis Wong | Chief Financial Officer | CAD 708.25K | — | — | — |
Vladimir Klacar | Senior Vice President of Operations | CAD 708.25K | 37 | — | — |
Ron Fichter | General Counsel & Corporate Secretary | CAD 674K | — | — | — |
Andrew MacMillan | Senior Vice President of Commercial | CAD 347.8K | — | — | — |
Kevin Furet | Chief Cultivation & Genetics Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +161.1% (3yr)1 analysts |
| Revenue | N/A | N/A | +17.0% | +14.8% (3yr)1 analysts |
| Net Income | N/A | N/A | N/A | +8.4% (3yr)1 analysts |
| EBIT | N/A | N/A | N/A | +31.3% (3yr)1 analysts |
Analysis
Recent growth has been strongest in Revenue at +17.0% over three years. Forward estimates point to EPS at +161.1% (3yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Auxly Cannabis Group Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about XLY.TO's management, answered from reported figures.
Who manages XLY.TO?
Auxly Cannabis Group Inc. (XLY.TO) lists 7 active executives. The top listed executive is Andrew MacMillan, Senior Vice President of Commercial.
Continue the stock analysis
Jump to another research area for this company.